TY - JOUR
T1 - The comparison of parotid gland carcinoma and submandibular gland carcinoma―Results of a multi institutional retrospective study
AU - Yamada, Koichiro
AU - Honda, Keigo
AU - Tanaka, Shinzo
AU - Tamaki, Hisanobu
AU - Kojima, Tsuyoshi
AU - Shinohara, Shogo
AU - Takebayashi, Shinji
AU - Maetani, Toshiki
AU - Asato, Ryo
AU - Tateya, Ichiro
AU - Kitamura, Morimasa
AU - Mizuta, Masanobu
AU - Kitani, Yoshiharu
AU - Ushiro, Koji
AU - Ichimaru, Kazuyuki
AU - Kumabe, Yohei
AU - Omori, Koichi
N1 - Publisher Copyright:
© 2018, Japan Society for Head and Neck Cancer. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Objective: Parotid gland carcinoma (PGC) and submandibular gland carcinoma (SMGC) are relatively rare. The aim of this retrospective study was to compare the clinical outcomes of PGC and SMGC. Patients: Our study included 260 patients(195 with PGC and 65 with SMGC) who underwent initial surgical treatment at Kyoto University and its affiliated hospitals between 2006 and 2015. Results: A total of 44% of the PGCs and 58% of the SMGCs were classified as high-grade malignancies. The sensitivity of fine-needle aspiration cytology was 50% for PGC and 75% for SMGC. At a mean follow-up time of 3.6 years, the 3-year overall survival, disease-specific survival (DSS), locoregional control, and no distant metastasis (NDM) rates for PGC were 85 %, 89 %, 85 %, and 87 %, respectively, while those for SMGC were 74 %, 74 %, 90 %, and 65 %, respectively. Furthermore, the DSS and NDM rates for SMGC were statistically significantly lower than those for PGC. Conclusions: In comparison to PGC, SMGC has a higher risk of distant metastasis and a poorer DSS rate.
AB - Objective: Parotid gland carcinoma (PGC) and submandibular gland carcinoma (SMGC) are relatively rare. The aim of this retrospective study was to compare the clinical outcomes of PGC and SMGC. Patients: Our study included 260 patients(195 with PGC and 65 with SMGC) who underwent initial surgical treatment at Kyoto University and its affiliated hospitals between 2006 and 2015. Results: A total of 44% of the PGCs and 58% of the SMGCs were classified as high-grade malignancies. The sensitivity of fine-needle aspiration cytology was 50% for PGC and 75% for SMGC. At a mean follow-up time of 3.6 years, the 3-year overall survival, disease-specific survival (DSS), locoregional control, and no distant metastasis (NDM) rates for PGC were 85 %, 89 %, 85 %, and 87 %, respectively, while those for SMGC were 74 %, 74 %, 90 %, and 65 %, respectively. Furthermore, the DSS and NDM rates for SMGC were statistically significantly lower than those for PGC. Conclusions: In comparison to PGC, SMGC has a higher risk of distant metastasis and a poorer DSS rate.
UR - http://www.scopus.com/inward/record.url?scp=85051242875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051242875&partnerID=8YFLogxK
U2 - 10.5981/jjhnc.44.39
DO - 10.5981/jjhnc.44.39
M3 - Article
AN - SCOPUS:85051242875
SN - 1349-5747
VL - 44
SP - 39
EP - 45
JO - Japanese Journal of Head and Neck Cancer
JF - Japanese Journal of Head and Neck Cancer
IS - 1
ER -